Author

H. Alborzinia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:statistical model· 1

Frequent Co-Authors

A. F. Florez· 1 shared A. Goncalves· 1 shared A. K. Miller· 1 shared A. Kopp-Schneider· 1 shared A. Teleman· 1 shared B. Nicke· 1 shared C. Brandstaedter· 1 shared C. Herrmann· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. F. Florez

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs

J. Samarin, P. Fabrowski, R. Kurilov, H. Nuskova, J. Hummel-Eisenbeiss, H. Pink, N. Li, V. Weru, H. Alborzinia, U. Yildiz, L. Grob, M. Taubert, M. Czech, M. Morgen, C. Brandstaedter, , N. Gunkel

The paper identifies antioxidant-capacity biomarkers (ACBs) that predict susceptibility to ROS-inducing drugs in lung cancer cells, showing that low ACB expression correlates with nitric oxide levels, not ROS levels.

bioRxiv · Jan 17, 2023Cancer Biology

MYCN mediates cysteine addiction and sensitizes to ferroptosis

H. Alborzinia, A. F. Florez, S. Gogolin, L. M. Brueckner, C. Shao, M. Gartlgruber, M. Nadler Holly, M. Ziehm, F. Paul, S. Steinhauser, E. Bell, M. Shaikhkarami, S. Hartlieb, D. Dreidax, E. M. Hess, , F. Westermann

This study shows MYCN promotes cysteine addiction and ferroptosis resistance in neuroblastoma, identifying therapeutic targets for ferroptosis induction.

bioRxiv · Aug 10, 2021 · PreprintCancer Biology